• Markets
  • icon
  • Companies
ADR · ASX

Adherium Ltd. (ASX:ADR)

AU$0.017

 -0.001 (-5.556%)
ASX:Live
17/05/2024 03:33:26 PM
HALO Ords GROWTH AUS Consensus Expensive All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

ADR Overview

ADR Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ADR

Telephone

N/A

Address

Description

Adherium Ltd. engages in the development, manufacture, and supply of digital health technologies. It operates through the following geographical segments: New Zealand and Australia, South-East Asian Countries, and Other Countries. The firm's Hailie system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. The company was founded by Garth Sutherland in 2001 and is headquartered in Melbourne, Australia.

ADR Price Chart

Key Stats

Market Cap

AU$12.24M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.09

Trade Value (12mth)

US$3,368.00

1 week

-10.53%

1 month

-36.39%

YTD

-69.29%

1 year

-60.42%

All time high

10.309100151062012

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

-366.90%

Operating Cashflow

-$9m

Free Cash Flow Return

-125.40%

ROIC

-133.30%

Interest Coverage

-1,953.50

Quick Ratio

3.30

Other Data

Shares on Issue (Fully Dilluted)

343m

HALO Sector

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

NZD

Short Sell (% of issue)

0.00

ADR Announcements

Latest Announcements

Date Announcements

16 May 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

15 May 24

Attending American Thoracic Society International Conference

×

Attending American Thoracic Society International Conference

13 May 24

Change in substantial holding

×

Change in substantial holding

10 May 24

Disclosure of Long Equity Derivative Positions

×

Disclosure of Long Equity Derivative Positions

08 May 24

Becoming a substantial holder

×

Becoming a substantial holder

07 May 24

Change in substantial holding

×

Change in substantial holding

06 May 24

Entitlement Offer Opens and Letters to Shareholders

×

Entitlement Offer Opens and Letters to Shareholders

03 May 24

Application for quotation of securities - ADR

×

Application for quotation of securities - ADR

01 May 24

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

29 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

26 April 24

Placement and Entitlement Offer to raise up to $8.37 million

×

Placement and Entitlement Offer to raise up to $8.37 million

26 April 24

Proposed issue of securities - ADR

×

Proposed issue of securities - ADR

26 April 24

Investor Presentation

×

Investor Presentation

26 April 24

Prospectus

×

Prospectus

23 April 24

Trading Halt

×

Trading Halt

18 April 24

Disclosure of Long Equity Derivative Positions

×

Disclosure of Long Equity Derivative Positions

17 April 24

Application for quotation of securities - ADR

×

Application for quotation of securities - ADR

17 April 24

Notification regarding unquoted securities - ADR

×

Notification regarding unquoted securities - ADR

15 April 24

US FDA clearance of Hailie for AstraZeneca inhalers

×

US FDA clearance of Hailie for AstraZeneca inhalers

04 April 24

Change of Director Interest Notices x 2 - Expiry of Options

×

Change of Director Interest Notices x 2 - Expiry of Options

03 April 24

Rimidi Partnership for Respiratory Clinical Management

×

Rimidi Partnership for Respiratory Clinical Management

02 April 24

Notification of cessation of securities - ADR

×

Notification of cessation of securities - ADR

27 March 24

Change in substantial holding

×

Change in substantial holding

20 March 24

First Patient Enrolled in Major e-health Clinical Study

×

First Patient Enrolled in Major e-health Clinical Study

07 March 24

Adherium receives $1.5m Australian R&D Tax Rebate

×

Adherium receives $1.5m Australian R&D Tax Rebate

ADR Fundamentals

Per Share Records

Historical data

Forecasted data

NZD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.00 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.00 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 53.7 72.5 -684.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.00 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.00 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 61.9 28.1 -629.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -73.8 -65.0 -91.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 0.03 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17.6 -62.0 1,002.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 901 2,174 272 Lock Lock Lock
Basic m Lock Lock Lock Lock 901 2,174 272 Lock Lock Lock

Financial Records

Historical data

Forecasted data

NZD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 1 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -81.9 31.9 504.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 12 12 14 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -1 2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -216.5 12.5 345.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -196.8 -130.4 53.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 297 230 47 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -12 -13 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -42.3 -3.6 7.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3,047.6 -2,392.2 -366.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -12 -13 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -38.6 -3.8 7.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3,083.8 -2,427.4 -372.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -15 -13 -12 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 -3 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -15 -10 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.9 33.2 1.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3,749.6 -1,898.7 -308.5 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -11 -10 -9 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 22 0 13 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -11 -10 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.6 12.5 5.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -28.2 -18.7 -2.9 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 15 5 9 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 17 9 13 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -15 -5 -9 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 3 3 3 Lock Lock Lock
Equity $m Lock Lock Lock Lock 14 6 9 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 14 6 9 Lock Lock Lock
     Growth % Lock Lock Lock Lock 314.7 -60.2 65.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -88.2 -117.7 -77.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -107.1 -181.4 -107.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -142.0 -130.7 -160.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -172.6 -102.4 -133.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -129.4 -98.0 -125.4 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

NZD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -5.5 -12,655.0 -1,953.5 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.2 0.4 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -108.1 -93.9 -98.0 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.6 2.8 3.6 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.3 2.4 3.3 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 89.8 64.3 72.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -375.3 -325.4 -267.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.7 0.5 1.8 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.1 1.2 1.3 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.1 0.4 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 174.8 63.3 30.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.3 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.3 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -3,841.9 -2,429.3 -366.1 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -90.4 -150.6 -92.2 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -88.2 -117.7 -77.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.5 1.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -107.1 -181.4 -107.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -107.1 -181.4 -107.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 319.3 304.4 280.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 523.8 738.3 203.4 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 843.1 1,042.6 483.9 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 301.3 142.4 141.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 541.8 900.3 342.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ADR Shortsell

Frequently Asked Questions

The current share price of Adherium Ltd. (ADR:ASX) is AU$0.017.
The 52-week high share price for Adherium Ltd. (ADR:ASX) is AU$0.09.
The 52-week low share price for Adherium Ltd. (ADR:ASX)? is AU$0.02.
Adherium Ltd. (ADR:ASX) does not pay a dividend.
Adherium Ltd. (ADR:ASX) does not pay a dividend.
Adherium Ltd. (ADR:ASX) has a franking level of 0.0%.
Adherium Ltd. (ADR:ASX) is classified in the Healthcare.
The current P/E ratio for Adherium Ltd. (ADR:ASX) is .